Replimune Group, Inc.
- Open
- 9.35
- Day high
- 10.31
- Day low
- 9.31
- Prev close
- 9.52
- Volume
- 3.7M
- Mkt cap
- $845M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.1
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$585K over the last 3 months (0 open-market buys, 7 sales)
- 🏛Institutions accumulating (13F)
Replimune Group, Inc. (REPL) is a Healthcare company listed on NASDAQ. The stock is down 15% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 7 sales (SEC Form 4).
Replimune Group, Inc. (REPL) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
REPL earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jun 29, 2026 | $-0.66 | $-0.76 | -14.9% | — | — |
| Feb 3, 2026 | $-0.85 | $-0.77 | +9.4% | — | — |
| Nov 6, 2025 | $-0.87 | $-0.90 | -3.4% | — | — |
| Aug 7, 2025 | $-0.83 | $-0.95 | -14.5% | — | — |
| May 22, 2025 | $-0.75 | $-0.82 | -9.3% | $1M | — |
| Feb 12, 2025 | $-0.70 | $-0.79 | -12.9% | — | — |
| Aug 8, 2024 | $-0.88 | $-0.78 | +11.4% | — | — |
| May 16, 2024 | $-0.86 | $-0.82 | +4.7% | $4M | — |
| Feb 8, 2024 | $-0.94 | $-0.77 | +18.1% | — | — |
| Aug 3, 2023 | $-0.85 | $-0.75 | +11.8% | — | — |
| May 18, 2023 | $-0.66 | $-0.74 | -12.1% | — | — |
| Feb 9, 2023 | $-0.77 | $-0.69 | +10.4% | — | — |
REPL insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 3, 2026 | Sarchi Christopherofficer: Chief Commercial Officer | Sell | 12,000 | $9.24 |
| May 20, 2026 | Astley-Sparke Philipdirector | Sell | 17,657 | $5.08 |
| May 20, 2026 | Patel Sushildirector, officer: Chief Executive Officer | Sell | 37,324 | $5.08 |
| May 20, 2026 | Schwendenman Andrewofficer: Chief Accounting Officer | Sell | 7,894 | $5.08 |
| May 20, 2026 | Hill Emily Luisaofficer: Chief Financial Officer | Sell | 7,812 | $5.08 |
| May 20, 2026 | Xynos Konstantinosofficer: Chief Medical Officer | Sell | 14,023 | $5.08 |
| May 20, 2026 | Sarchi Christopherofficer: Chief Commercial Officer | Sell | 8,626 | $5.08 |
| Apr 7, 2026 | Schwendenman Andrewofficer: Chief Accounting Officer | Grant | 36,667 | — |
| Apr 7, 2026 | Xynos Konstantinosofficer: Chief Medical Officer | Grant | 50,000 | — |
| Apr 7, 2026 | SLATTERY JOSEPH Pdirector | Grant | 44,500 | $7.61 |
| Apr 7, 2026 | Dhingra Kapildirector | Grant | 44,500 | $7.61 |
| Apr 7, 2026 | Hill Emily Luisaofficer: Chief Financial Officer | Grant | 75,000 | $7.61 |
| Apr 7, 2026 | Patel Sushildirector, officer: Chief Executive Officer | Grant | 251,240 | — |
| Apr 7, 2026 | Xynos Konstantinosofficer: Chief Medical Officer | Grant | 75,000 | $7.61 |
| Apr 7, 2026 | Sarchi Christopherofficer: Chief Commercial Officer | Grant | 75,000 | $7.61 |
Source: REPL SEC Form 4 filings, latest Jun 3, 2026. For informational purposes only — not investment advice.
See the full REPL insider & 13F page →Replimune Group, Inc. company profile
Overview
Replimune Group, Inc. (NASDAQ:REPL) is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company went public in July 2018 and specializes in developing oncolytic immuno-gene therapies, a cutting-edge approach to cancer treatment that uses genetically modified viruses to selectively target and destroy cancer cells while simultaneously activating the patient's immune system. Replimune is currently preparing for the potential commercial launch of its lead product candidate RP1, which has received breakthrough therapy designation from the FDA and has a Prescription Drug User Fee Act (PDUFA) date of July 22, 2025.
Business
Replimune operates in the oncolytic immunotherapy sector of biotechnology, which represents an innovative approach to cancer treatment. The company's core technology platform uses specially engineered viruses that can selectively replicate within cancer cells, causing them to burst and die while leaving healthy cells unharmed. This viral destruction of cancer cells also releases tumor antigens and inflammatory signals that help activate the patient's own immune system to recognize and attack remaining cancer cells throughout the body. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 (HSV-1) that has been genetically modified to enhance its cancer-fighting properties. RP1 is administered through direct injection into tumors and is currently in Phase II clinical trials for patients with cutaneous squamous cell carcinoma and Phase I/II trials for various solid tumors. The treatment is designed for patients whose cancer has progressed despite treatment with PD-1 inhibitors, a class of immunotherapy drugs. The company is also developing next-generation candidates including RP2, which incorporates an anti-CTLA-4 antibody-like protein to further enhance immune activation, and RP3, which expresses additional immune-stimulating proteins. These candidates are currently in Phase I clinical trials. Replimune's pipeline focuses on addressing the significant unmet medical need in patients with advanced solid tumors who have exhausted standard treatment options.
Revenue model
As a pre-revenue biotechnology company, Replimune currently generates no product sales revenue and operates on a research and development-focused business model funded by equity capital and partnerships. The company's future revenue model will be based on product sales of approved therapies to hospitals and cancer treatment centers, with pricing expected to reflect the high value and specialized nature of oncolytic immunotherapy treatments. The primary paying customers will be hospital systems, comprehensive cancer centers, and specialty oncology clinics that treat patients with advanced solid tumors. Given the specialized administration requirements involving direct tumor injection, the treatment will likely be concentrated in major medical centers with interventional radiology capabilities. The company estimates approximately 13,000 patients progress on PD-1 treatment annually in the United States, with roughly 80% potentially eligible for RP1 treatment. Several factors could significantly impact future margins and profitability. Positive factors include the company's breakthrough therapy designation which may facilitate faster regulatory approval and premium pricing, the specialized nature of the treatment which could support higher margins, and the company's in-house manufacturing capabilities which provide cost control. Challenging factors include the high cost of clinical trials and regulatory compliance, the specialized distribution and administration requirements that may limit market penetration, competitive pressure from other immunotherapy approaches, and the inherent risks of biotechnology development where clinical trial failures could eliminate revenue potential entirely.
Competitive moat
Replimune's competitive moat is primarily built on its proprietary oncolytic virus platform and specialized expertise in engineering herpes simplex viruses for cancer treatment. The company has developed significant intellectual property around its viral engineering techniques and has established manufacturing capabilities that create barriers to entry. The breakthrough therapy designation for RP1 provides regulatory advantages and potentially faster market access compared to competitors. However, the moat strength is moderate to weak at this stage of development. The oncolytic immunotherapy field is highly competitive with multiple companies developing similar approaches using different viral platforms, including Amgen's T-VEC (already approved), and various other HSV-based therapies in development. The company's intellectual property, while valuable, may not provide insurmountable barriers as competitors can potentially develop alternative viral vectors or delivery mechanisms. The most significant competitive threats come from established pharmaceutical companies with greater resources, alternative immunotherapy approaches that may prove more effective or easier to administer, and the general risk that the entire oncolytic virus approach may be superseded by other cancer treatment modalities such as CAR-T cell therapies, antibody-drug conjugates, or next-generation checkpoint inhibitors. The company's success will largely depend on demonstrating superior clinical outcomes and establishing strong relationships with key cancer treatment centers before competitors can gain significant market share.
Risks & safety
The margin of safety is moderate given the company's strong cash position but substantial execution risks inherent in biotechnology development. • Cash and liquidity: $483.8 million in cash and short-term investments as of Q4 2025, providing runway into Q4 2026 with current burn rate of approximately $65-75 million per quarter • Debt level: Minimal debt with debt-to-equity ratio near zero, eliminating solvency risk from leverage • Valuation metrics: Trading at approximately 1.9x price-to-book ratio, which appears reasonable for a late-stage biotech with near-term commercialization potential • Binary risk factors: Primary risk is regulatory approval - PDUFA date of July 22, 2025 represents a major catalyst that could dramatically impact valuation either positively or negatively • Commercial execution risk: Even with approval, the company faces significant challenges in market penetration given the specialized administration requirements and competitive landscape
Recent development
Over the past few years, Replimune has made substantial progress toward commercialization of RP1. The company received breakthrough therapy designation from the FDA for RP1 in anti-PD-1 failed melanoma, which provides regulatory advantages and reflects the FDA's recognition of the treatment's potential. The company has completed critical regulatory milestones including late-cycle meetings with the FDA and manufacturing facility inspections, positioning it for the July 22, 2025 PDUFA date. On the commercial preparation front, Replimune has built a commercial team of 60 people and established relationships with specialty distributors for product distribution. The company has created a new role called Interventional Radiology Oncology Coordinator (IROC) to support the specialized administration requirements of tumor injection. They have identified approximately 350 top accounts and report that over 90% of surveyed providers indicate willingness to use RP1 upon approval. The company has also been advancing its pipeline beyond RP1, with development plans for RP2 in uveal melanoma and hepatocellular carcinoma. Management has indicated a strategic focus on building an "RPX platform" for interventional immuno-oncology, suggesting plans to develop additional oncolytic therapies. An investor day planned for June 24 is expected to provide more details on the company's future pipeline strategy and commercial outlook.
REPL company profile · for informational purposes only — not investment advice.
Track REPL with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free